PTHS — Pelthos Therapeutics Inc.

Summary of Pelthos Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Product Revenue: Increased by 28% from $7.1 million in Q3 2025 to $9.1 million in Q4 2025.
• Prescriptions: Rose 129% from 2,716 units in Q3 to 6,232 units in Q4.
• Cost of Goods Sold: $4.0 million for the year, with $1.7 million in Q4.
• Gross to Net (GTN) Discount: Reported at 28.7%, with expectations to rise to the mid- to upper 30% range.
• Operating Loss: Improved from $15.4 million in Q3 to $12.0 million in Q4; adjusted EBITDA loss improved from $11.5 million to $9.0 million.
• Cash Position: Ended Q4 with $18.0 million in cash and $8.9 million in accounts receivable.

2. Strategic Updates and Business Highlights

• ZELSUVMI Launch: Strong demand post-launch with significant prescription growth, establishing it as a first-line treatment for molluscum contagiosum (MC).
• Product Acquisitions: Acquired two FDA-approved products, Xepi (for impetigo) and Xeglyze (for head lice), expected to launch in early 2027 and mid-2027, respectively.
• Sales Force Expansion: Increased from 50 to 64 territory managers to enhance market penetration.
• Market Access: Entered a contract with a pharmacy benefit manager (PBM) covering 20 million lives, improving patient access.

3. Forward Guidance and Outlook

• Revenue Growth: Management is optimistic about continued growth, particularly with the upcoming launches of Xepi and Xeglyze.
• Profitability Timeline: Anticipates ZELSUVMI may become profitable by the end of 2026, contingent on maintaining current business plans and execution.
• Sales Strategy: Focus on increasing the breadth of prescribers while managing inventory levels to avoid stockouts.

4. Bad News, Challenges, or Points of Concern

• Seasonality Effects: Q4 is typically a weaker quarter for MC claims, and January 2026 did not see the expected rebound in patient visits.
• Increased SG&A Expenses: While cash SG&A decreased slightly, future increases are expected due to the expanded sales force and preparations for new product launches.
• Competitive Pressures: Concerns about competition from other treatments, particularly regarding market access and physician adoption.

5. Notable Q&A Insights

• Competitive Dynamics: Management believes both Pelthos and competitors can thrive in the market, emphasizing ZELSUVMI's unique at-home treatment advantage.
• Sales Strategy: The focus remains on expanding the prescriber base, with nearly 4,000 unique prescribers recorded by early March 2026.
• Market Awareness: Digital marketing efforts, including a successful YouTube campaign, are driving patient inquiries about ZELSUVMI.
• Future Product Strategy: While currently focused on ZELSUVMI, the company remains open to acquiring additional complementary products if they align with strategic goals.

Overall, Pelthos Therapeutics is experiencing strong growth driven by the successful launch of ZELSUVMI and strategic acquisitions, though it faces challenges related to seasonality, rising expenses, and competitive pressures.